Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease
Recruiting · NCT06300788 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Hospitalier Universitaire de Nice
View the official record on ClinicalTrials.gov →Interventions studied
PPI and T50 dosing
What this trial is about
The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.
Who can take part
Age range
0 Years to 18 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- All groups :
- Minor patients (\<18 years)
- Patients of both sexes
- Informed patients and parents who have signed the informed consent form
- Patients affiliated to social security
- Control group :
- \- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up
- CKD groups :
- Patients on dialysis for more than 3 months, regardless of technique
- Kidney transplant patients
- Patients with CKD, whatever the cause
Exclusion criteria
- Progressive cancer or kidney disease
- Treatments that may modify PPi concentration (e.g. bisphosphonates)
Where it is running
1 location listed.
- CHU Nice - Hôpital de l'Archet 2 - Nice, Alpes-Maritimes, France